First-in-class drug approvals
Number of approved therapeutic drugs featuring a novel biological mechanism of action.
Unit Count Industry Pharmaceuticals
The chart
Over time
China over time. Forecasts are dashed with hollow markers; the underlying values are one click away under the chart.
First-in-class drug approvals
China, 2022 to 2025
Every record
All records
9 records · 1 region · 2022–2025
| Period | Value | Source | Type |
|---|---|---|---|
| China 9 records | |||
| 2025 | 11 | NHSA · 31 Dec 2025 | actual |
| 2025 | 11 | MOFCOM · 31 Dec 2025 | actual |
| 2024 | 48 | NMPA · 31 Dec 2024 | actual |
| 2024 | 48 | State Council · 31 Dec 2024 | actual |
| 2024 | 48 | NMPA · 31 Dec 2024 | actual |
| 2023 | 40 | State Council · 31 Dec 2023 | actual |
| 2023 | 40 | NMPA · 31 Dec 2023 | actual |
| 2022 | 21 | State Council · 31 Dec 2022 | actual |
| 2022 | 21 | NMPA · 31 Dec 2022 | actual |
Primary documents
Sources
5 documents. Each links to the publisher's own copy.
| Document | Publisher | Published | Data points |
|---|---|---|---|
| 2025年我国批准创新药76个 对外授权超千亿美元 | MOFCOM | — | 1 |
| 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元 | NHSA | — | 1 |
| China approves 48 innovative drugs in 2024 | NMPA | — | 1 |
| Measures facilitate approval of 48 first-in-class innovative drugs | NMPA | — | 3 |
| Measures facilitate approval of 48 first-in-class innovative drugs | State Council | — | 3 |
Cite & reuse
Cite this page
Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it. To cite one figure, open its record: each carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). First-in-class drug approvals. Retrieved from https://statorigin.org/indicators/first-in-class-drug-approvals